26.94
price up icon0.95%   0.2768
 
loading
전일 마감가:
$26.66
열려 있는:
$26.81
하루 거래량:
1.24M
Relative Volume:
0.71
시가총액:
$4.44B
수익:
$1.51B
순이익/손실:
$333.35M
주가수익비율:
13.81
EPS:
1.95
순현금흐름:
$315.22M
1주 성능:
-6.71%
1개월 성능:
-7.48%
6개월 성능:
-10.91%
1년 성능:
+8.52%
1일 변동 폭
Value
$26.35
$26.99
1주일 범위
Value
$26.05
$29.74
52주 변동 폭
Value
$24.62
$36.45

Alkermes Plc Stock (ALKS) Company Profile

Name
명칭
Alkermes Plc
Name
전화
00-353-1-772-8000
Name
주소
CONNAUGHT HOUSE, DUBLIN 4
Name
직원
1,800
Name
트위터
@alkermes
Name
다음 수익 날짜
2024-10-24
Name
최신 SEC 제출 서류
Name
ALKS's Discussions on Twitter

ALKS을(를) 다른 주식과 비교

주식 가격 시가총액 매출 순이익 현금흐름 주당 순 이익
Drug Manufacturers - Specialty & Generic icon
ALKS
Alkermes Plc
26.95 4.90B 1.51B 333.35M 315.22M 1.95
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
149.31 69.30B 9.29B 2.52B 2.28B 5.57
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.55 47.50B 30.08B 710.16M 4.45B 0.2182
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.60 44.47B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.19 18.83B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
297.62 13.43B 2.99B 1.21B 1.13B 25.06

Alkermes Plc Stock (ALKS) Upgrades & Downgrades

날짜 액션 분석자 등급 변경
2025-07-15 개시 Goldman Buy
2025-06-17 업그레이드 UBS Neutral → Buy
2025-05-28 개시 Needham Buy
2025-03-13 개시 RBC Capital Mkts Sector Perform
2025-03-04 업그레이드 UBS Sell → Neutral
2025-02-11 개시 Deutsche Bank Buy
2024-11-05 업그레이드 Stifel Hold → Buy
2024-06-17 개시 TD Cowen Buy
2024-03-19 개시 Robert W. Baird Outperform
2024-02-20 다운그레이드 UBS Neutral → Sell
2023-11-20 재개 JP Morgan Neutral
2023-10-24 업그레이드 Evercore ISI In-line → Outperform
2023-10-17 개시 UBS Neutral
2022-11-03 업그레이드 Piper Sandler Neutral → Overweight
2022-10-14 업그레이드 BofA Securities Underperform → Neutral
2022-08-16 개시 Piper Sandler Neutral
2022-04-22 재개 Goldman Buy
2022-04-20 개시 Goldman Buy
2022-01-27 업그레이드 Cantor Fitzgerald Hold → Overweight
2021-12-01 개시 Citigroup Neutral
2021-10-07 업그레이드 Jefferies Hold → Buy
2021-09-02 다운그레이드 BofA Securities Neutral → Underperform
2020-10-15 업그레이드 Mizuho Neutral → Buy
2020-07-30 다운그레이드 Goldman Neutral → Sell
2020-02-14 다운그레이드 BofA/Merrill Buy → Neutral
2020-02-14 재확인 H.C. Wainwright Neutral
2020-02-14 다운그레이드 JP Morgan Overweight → Neutral
2020-02-06 개시 Mizuho Neutral
2020-01-31 업그레이드 Wolfe Research Underperform → Peer Perform
2019-09-05 업그레이드 Morgan Stanley Underweight → Equal-Weight
2019-07-15 업그레이드 Goldman Sell → Neutral
2019-05-31 개시 H.C. Wainwright Neutral
2019-05-01 다운그레이드 Citigroup Buy → Neutral
2018-12-19 다운그레이드 Goldman Neutral → Sell
2018-12-14 개시 Wolfe Research Underperform
2018-12-13 다운그레이드 Credit Suisse Outperform → Underperform
2018-11-05 개시 Piper Jaffray Neutral
2018-08-07 개시 Stifel Hold
2018-06-21 다운그레이드 Morgan Stanley Equal-Weight → Underweight
2018-06-06 개시 B. Riley FBR, Inc. Buy
2018-05-16 업그레이드 Citigroup Neutral → Buy
2018-05-11 개시 BofA/Merrill Buy
모두보기

Alkermes Plc 주식(ALKS)의 최신 뉴스

pulisher
10:00 AM

Alkermes (ALKS) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance

10:00 AM
pulisher
09:39 AM

ALKS Down Despite Positive Top-Line Data From Narcolepsy Study - TradingView

09:39 AM
pulisher
07:59 AM

Is Alkermes plc a good long term investmentPhenomenal returns - jammulinksnews.com

07:59 AM
pulisher
Jul 21, 2025

What drives Alkermes plc stock priceFree Consultation - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

What analysts say about Alkermes plc stockOutstanding capital returns - Autocar Professional

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes plc (NASDAQ:ALKS) Launches Phase II Trial of ALKS 2680 for Idiopathic Hypersomnia - Yahoo Finance

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Phase 2 Study Results - TipRanks

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes To Advance Alixorexton After Positive Phase II Narcolepsy Results - insights.citeline.com

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives. - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Oral Drug Helps Patients Stay Awake In Mid-Stage Sleep Disorder Study - inkl

Jul 21, 2025
pulisher
Jul 21, 2025

Why Is Alkermes Stock Falling On Monday?Alkermes (NASDAQ:ALKS) - Benzinga

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug headed for late-stage testing - BioPharma Dive

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes stock rating reiterated as Buy by Stifel after positive narcolepsy data - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Vibrance-1 Phase 2 Study Of Alixorexton In Narcolepsy Type 1 Meets Primary Goal - Nasdaq

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes announces positive topline results from Vibrance-1 Phase 2 study - MarketScreener

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes narcolepsy drug shows positive results in phase 2 trial By Investing.com - Investing.com UK

Jul 21, 2025
pulisher
Jul 21, 2025

Alkermes Announces Positive Topline Results From Vibrance-1 Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1 - PR Newswire

Jul 21, 2025
pulisher
Jul 20, 2025

Is Alkermes Plc's (NASDAQ:ALKS) Latest Stock Performance Being Led By Its Strong Fundamentals? - 富途牛牛

Jul 20, 2025
pulisher
Jul 20, 2025

Alkermes plc Stock Analysis and ForecastRecord-breaking capital gains - Autocar Professional

Jul 20, 2025
pulisher
Jul 19, 2025

10 Most Undervalued Pharma Stocks To Buy Now - Insider Monkey

Jul 19, 2025
pulisher
Jul 18, 2025

Goldman Sachs Initiates Alkermes (ALKS) with a Buy Rating - MSN

Jul 18, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% By Investing.com - Investing.com India

Jul 17, 2025
pulisher
Jul 17, 2025

BlackRock increases stake in Alkermes to 17.05% - Investing.com

Jul 17, 2025
pulisher
Jul 15, 2025

Alkermes to Release Q2 Financial Results on July 29, 2025 - AInvest

Jul 15, 2025
pulisher
Jul 15, 2025

Alkermes to Report Second Quarter Financial Results on July 29, 2025 - MarketScreener

Jul 15, 2025
pulisher
Jul 15, 2025

Expert Outlook: Alkermes Through The Eyes Of 6 Analysts - Benzinga

Jul 15, 2025
pulisher
Jul 15, 2025

Goldman Sachs Initiates Coverage on Alkermes (ALKS) with a Buy R - GuruFocus

Jul 15, 2025
pulisher
Jul 14, 2025

How Much Upside is Left in Alkermes (ALKS)? Wall Street Analysts Think 33.19% - Yahoo Finance

Jul 14, 2025
pulisher
Jul 14, 2025

(ALKS) Pivots Trading Plans and Risk Controls - news.stocktradersdaily.com

Jul 14, 2025
pulisher
Jul 08, 2025

Alkermes (NASDAQ:ALKS) shareholders have earned a 9.3% CAGR over the last five years - simplywall.st

Jul 08, 2025
pulisher
Jul 03, 2025

INVESTOR ALERT: Levi & Korsinsky, LLP Reminds Shareholders of Alkermes plc of a Class Action Lawsuit and a Lead Plaintiff Deadline of January 22, 2018ALKS - ACCESS Newswire

Jul 03, 2025
pulisher
Jul 03, 2025

Zacks Industry Outlook Highlights Exelixis, Verona Pharma, Alkermes, Kiniska Pharmaceuticals and Immunocore - Yahoo Finance

Jul 03, 2025
pulisher
Jun 30, 2025

Alkermes plc(NasdaqGS: ALKS) added to Russell 2500 Value Index - MarketScreener

Jun 30, 2025
pulisher
Jun 26, 2025

Alkermes spinoff Mural plunges on plans to halt ovarian cancer trial - MSN

Jun 26, 2025
pulisher
Jun 23, 2025

(ALKS) On The My Stocks Page - news.stocktradersdaily.com

Jun 23, 2025
pulisher
Jun 18, 2025

Alkermes Gains Momentum With Promising Narcolepsy Drug - Finimize

Jun 18, 2025
pulisher
Jun 18, 2025

Alkermes (ALKS) Upgraded by UBS with Positive Development Prospe - GuruFocus

Jun 18, 2025
pulisher
Jun 17, 2025

Alkermes stock upgraded at UBS on sleep disorder drug (ALKS) - Seeking Alpha

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes' ALKS-2680 Seen as Potential Breakthrough for Narcolepsy, Hypersomnia, BofA Says - MarketScreener

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | A - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Gains Upgrade from UBS with Positive Outlook | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Nvidia To Rally More Than 38%? Here Are 10 Top Analyst Forecasts For Tuesday - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stoc - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

This Cooper Companies Analyst Turns Bullish; Here Are Top 3 Upgrades For Tuesday - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Buy Rating Upgrade from UBS | ALKS Stock News - GuruFocus

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes Stock: A Deep Dive Into Analyst Perspectives (6 Ratings) - Benzinga

Jun 17, 2025
pulisher
Jun 17, 2025

UBS Upgrades Alkermes Public to Buy From Neutral, Adjusts Price Target to $42 From $33 - marketscreener.com

Jun 17, 2025
pulisher
Jun 17, 2025

Alkermes (ALKS) Receives Upgrade as Prospects Brighten for Narco - GuruFocus

Jun 17, 2025

Alkermes Plc (ALKS) 재무 분석

매출

loading

순이익

loading

현금흐름

loading

주당 순 이익

loading

Alkermes Plc 주식 (ALKS) 내부자 거래

내부자 거래 관계 날짜 거래 비용 #주식 가치 ($) #주식 총계
Nichols Christian Todd
SVP, Chief Commercial Officer
Jun 10 '25
Sale
31.09
3,334
103,654
86,208
$71.33
price down icon 0.37%
$14.86
price up icon 1.19%
$8.98
price up icon 0.45%
drug_manufacturers_specialty_generic RDY
$14.40
price down icon 1.07%
$133.00
price up icon 0.51%
$297.48
price up icon 1.53%
자본화:     |  볼륨(24시간):